Dr. Xue Meng 孟雪
Chief Physician, Associate Professor
Department of Thoracic Radiation Oncology I, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Precision treatment of thoracic tumors, with a focus on the basic application and clinical translation of functional and molecular imaging.
Dr. Meng holds a PhD in Oncology and serves as Associate Professor and Chief Physician. Trained under Academician Yu Jinming, Dr. Meng has over 13 years of clinical experience and more than 15 years of research in molecular imaging for thoracic tumors. Dr. Meng was a visiting scholar at MD Anderson Cancer Center and the University of Michigan.
Professional roles
- Chair, Tumor Immunology and Immunotherapy Branch, Shandong Anti-Cancer Association
- Standing Committee Member, Youth Council, Shandong Anti-Cancer Association
- Member, Lung Cancer Group, Professional Committee on Tumor Radiotherapy, China Anti-Cancer Association
- Youth Editorial Board Member, Global Oncology News
Name order: in Chinese the family name comes first (Meng Xue). Papers usually list the name as Xue Meng or Meng X.
Selected publications
121 papers on PubMed matched by name and affiliation; 45 as first or senior author since 2016. Most recent first- or senior-author papers:
- iScience, 2026 (senior author): ADAR1 regulates radiosensitivity in ESCC through cIAP2-NF-κB signaling and C16orf46 editing. PubMed 42548802
- Clin Cancer Res, 2026 (senior author): Low-Dose Intestinal Irradiation Enhances the Efficacy and Prognosis of PD-1 Blockade in Metastatic Non-Small Cell Lung Cancer. PubMed 41849236
- Int J Cancer, 2026 (senior author): Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors. PubMed 41872688
- J Immunother Cancer, 2026 (senior author): Neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB non-small cell lung cancer: integrated multidimensional biomarker analysis from a phase II study. PubMed 42320986
- Mol Cancer, 2026 (senior author): ROCK1 inhibition primes anti-tumor immunity in EGFR-mutant NSCLC by triggering PD-L1 degradation mediated by SMURF2. PubMed 41928228
- Int J Radiat Oncol Biol Phys, 2026 (senior author): Proton Therapy May Reduce the Risk of Cancer Progression During Immune Checkpoint Inhibitor Therapy: A Propensity Score-Matched Analysis of Intensity Modulated Proton Versus Photon Radiation Therapy. PubMed 41043559
- Cancer Lett, 2026 (first author): Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer. PubMed 41419100
- Int J Surg, 2026 (senior author): Neoadjuvant tislelizumab with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma. PubMed 41292221
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion